GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » Total Inventories

Singular Genomics Systems (Singular Genomics Systems) Total Inventories : $13.08 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems Total Inventories?

Singular Genomics Systems's total inventories for the quarter that ended in Mar. 2024 was $13.08 Mil. Singular Genomics Systems's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $13.33 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Singular Genomics Systems's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Singular Genomics Systems's Days Inventory for the three months ended in Mar. 2024 was 1,412.36.

Inventory Turnover measures how fast the company turns over its inventory within a year. Singular Genomics Systems's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.06.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Singular Genomics Systems's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 30.15.


Singular Genomics Systems Total Inventories Historical Data

The historical data trend for Singular Genomics Systems's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Singular Genomics Systems Total Inventories Chart

Singular Genomics Systems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
- - 3.01 18.22 13.57

Singular Genomics Systems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.16 14.35 13.42 13.57 13.08

Singular Genomics Systems Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Singular Genomics Systems  (NAS:OMIC) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Singular Genomics Systems's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(150.738+0.75 * 0.137+0.5 * 13.081-82.403
-0-0)/74.0674
=1.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Singular Genomics Systems's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=13.3265/0.861*365 / 4
=1,412.36

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Singular Genomics Systems's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=0.861 / 13.3265
=0.06

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Singular Genomics Systems's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=13.3265 / 0.442
=30.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Singular Genomics Systems Total Inventories Related Terms

Thank you for viewing the detailed overview of Singular Genomics Systems's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Singular Genomics Systems (Singular Genomics Systems) Business Description

Traded in Other Exchanges
N/A
Address
3010 Science Park Road, San Diego, CA, USA, 92121
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Executives
Andrew Spaventa director, 10 percent owner, officer: Chief Executive Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer officer: Chief Scientific Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai officer: Chief Operating Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp officer: Chief Commercial Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis director 301 MERRITT 7, NORWALK CT 06851
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly officer: President and Chief Operating 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio officer: Vice President, HR 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter officer: Vice President, Finance 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie officer: General Counsel 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde officer: Senior Vice President 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121